ANTIVIRAL SUBSTANCE Fl~O~[ PENICILLIUM FUNICULOSUM. VI ments each represented a pool of the serums of several animals. The anti-Semliki serum of mouse origin was obtained from pools of mice that had survived two or more injections of virus in experiments in which immunity had been conferred by various procedures. The anesthetized animals were bled by decapitation and the blood, after dotting, was either ground in a TenBroeck grinder with the addition of one part of saline, containing 10 mg of streptomycin sulfate and 2000 units of penicillin G per ml, to each two parts of mouse blood, or serum was collected by centrifugation in the usual manner. So far as could be told, there was no difference in the results obtained whether ground whole mouse blood or mouse serum alone was employed.
In the experiments to be outlined, the antiviral serum was, except as otherwise noted, injected intraperitoneally and helenine, where employed in conjunction with serum, was also administered intraperitoneally. Both the antiserum and the helenine were given in 0.5 ce amounts to each animal. In instances in which mixtures of antiserum and helenine were administered, the mixing was done just prior to inoculation and the total amount of the mixture injected was 1 cc. Inoculation with virus was routinely by the subcutaneous route under the loose skin of the back.
RESULTS

Prevention of the Establishment of Passive Immunity by lteterologous Antiviral Serum in Mice Treated vatk Helenine
Groups of mice were injected intraperitoneally with anti-Semliki serum of swine origin 4, 8, 12, 16 , and 21 days before inoculation subcutaneously with Semliki Forest virus. To a portion of themice in each group, the antiserum injection was followed 2 hr later by an intraperitoneal injection of helenine. The results gotten in several separate experiments have been combined and recorded in Table I . As shown in this table, most of the mice in the groups receiving antiserum alone survived challenge with a dose of virus that killed all of 22 control mice, regardless of whether the antiserum preceded the virus by 4, 8, 12, 16, or 21 days. Similarly, most of the mice that received antiserum and helenine 4 and 8 days before virus inoculation also survived. However, of the groups of mice that had been given antiserum and helenine 12, 16, and 21 days before virus inoculation, the findings were quite different. Here 8 of the 14 mice treated 12 days before infection survived while only 1 each of the groups of 14 treated 16 and 21 days before inoculation failed to succumb to the virus infection.
The animals surviving initial infection with virus in all groups were then rechallenged 12 to 15 days later with the same dose of virus they had initially withstood. Again most of the mice that had received only anti-Semliki serum withstood rechallenge with the same dose of virus they had initially survived. However, of the mice that had survived infection 4, 8, and 12 days after receiving antiserum and helenine, most succumbed on later rechallenge with virus. They thus behaved on rechMlenge similarly to those groups challenged initially 16 and 21 days after antiserum and helenine.
It is apparent from these findings that although anti-Semliki serum of swine origin can passively protect mice against infection with Semliki Forest virus for at least as long as 21 days, helenine prevents the establishment of this passive immunity. The findings recorded in Table I further indicate that, to demonstrate blocking of the establishment of passive protection, a period of time longer than 8 days must elapse between the administration of the antiserum and helenine and challenge with virus. It is believed that excess antibody remains available~ unaffected by helenine, for at least this long, and that this available antibody persisting, perhaps in circulation, accounts for the result gotten in the groups of mice challenged with virus 4 and 8 days after antiserum and helenine. That persisting passive protection did not establish even in these groups is indicated by their fully fatal susceptibility to infection with virus when rechallenged 12 or 15 days later. Persistent, of Passive Immunity in Mice Conferred by Swine Anti-S~nliki Serum.uThe findings oufllned in the preceding section and recorded in Table  I indicated that anti-Semliki Forest virus serum of swine origin conferred solid passive protection in mice against the virus for at least 21 days whereas mice given the same serum and then treated with helenine had lost their passive protection by 16 days. It seemed of interest in the light of these findings to deter-mine just how long passive protection to the virus might persist following the administration of swine antiviral serum.
Four groups of 7 mice each were injected with swine anti-Semliki serum and then at intervals of roughly 3, 4, 5, and 8 wk were challenged with a dose of Semliki Forest virus sufficient to cause death of all the control animals.
As shown by the results recorded in Table II , all of the mice challenged 18 days after antiserum and most of those challenged at 27 and 39 days survived an ordinarily fatal dose of Semliki Forest virus. However by 58 days, the passive protection conferred by the antiserum had completely waned and all 7 mice succumbed to the challenge infection. The period of adequate persistence of passive protection conferred by swine anti-Semliki serum is therefore something more than approximately 5 wk but less than approximately 8 wk.
In~uence of the Time of Administration of ttdenine on Its Ability to Prevent the Establishment of Passive Immunity by Antiviral Serum
In an earlier paper dealing with the antiviral effect of helenine on mice infected with Semliki Forest virus, it was shown that the optimal effect was achieved if the helenine was administered during a 36 hr period extending from 12 to 48 hr before infection (2) . With the view in mind that the optimal time of effectiveness of helenine in preventing the establishment of passive immunity by antiviral serum might correspond to that during which it was known to exert its optimal effect on virus infection, experiments were carried out in which helenine was given at various time intervals before and after the administration of antiviral serum. If the timing of maximal effectiveness of helenine in reproducing the two phenomena was similar, the possibility would be apparent that they might result from some common effect of helenine on the host.
In the experiments to be described, groups of mice were given anti-Semliki serum of swine origin intraperitoneally. Some of these received no further treatment while others were given helenine intraperitoneally at various intervals before or after the antiserum. All, together with untreated control mice of the same age, were inoculated subcutaneously with Semllki Forest virus 3 wk after their serum treatments. The results given in Table III represent a composite of the findings in the experiments that have been carded out.
As shown in Table III , 39 of 49 of the mice that received anti-Semliki serum alone 3 wk before infection survived a dose of virus that killed all except 1 of 36 control mice. Helenine mixed with the antiviral serum at time of administration or injected from 2 hr to 4 days prior to antiserum interfered materially with the establishment of passive protection by antiviral serum. Helenine injected from 2 hr to as long as 2 days after antiviral serum administration also prevented or diminished the establishment of passive viral immunity. Helenine given 3, 4, and 7 days after antiviral serum was without obvious effect on the capacity of antiserum passively to protect mice. It thus appeared that the period of time during which helenine was effective in suppressing the establishment of passive protection by antiviral serum covered a span of 6 days extending from at least 4 days before to 2 days after the serum administration. While this 6 day period embraced the 36 hr period during which, as had been shown by earlier work (2), helenine was optimally effective in exerting an antiviral action, it was apparent either that the mechanism by which the passive immunity suppression was brought about differed from that by which the antiviral action, was effected or that, ff the mechanisms involved were similar, there were quantitative differences in the sensitivity in which they were expressed by the host. Since evidence has been adduced to indicate strongly that the antiviral effect of helenine results from the induction of interferon by the treated host (3), it is apparent that the passive immunity suppressing effect of helenine either is not mediated by helenine-induced interferon or, if it is so mediated, the sensitivity of the host differs materially in the expressions of the two phenomena.
Failure of ttelenine to Prevent the Establishment of Passive Immunity in Mice by Homologous Antivirat Serum
From the findings of the experiment outlined in Table I , it was apparent that the site of action of helenine in preventing the establishment of passive immunity following the administration of antiviral serum was not on antibody that persisted in circulation following its administration. Rather the lapse of a period in excess of 8 days for the acquisition of full effectiveness in blocking passive immunity suggested that either helenine acted to prevent the fixation of antibody to some cellular site in the host where it was stored, or in some obscure manner, effected the early destruction of antibody. Since the antibody in the initial experiment was swine protein, the question arose as to whether this blocking or destructive effect by helenine would be equally effective against homologous antibody of mouse origin. In order to attempt to answer the question, an experiment was conducted in which anti-Semliki serum of mouse origin was substituted for the swine antiviral serum.
In this experiment, 25 mice were given mouse anti-Semliki serum and another 25 received the same serum followed 2 hr later by helenine. 21 days later these animals, together with 18 control mice of the same age, were challenged with Semiiki Forest virus. As shown in Table IV , of the mice in the two treated groups, all in both groups except one that received antiserum alone survived, while the control animals died. Helenine had therefore failed to prevent the establishment of passive immunity from mouse anti-Semliki serum, a result quite the opposite of what had been found when swine antiviral serum had been employed to establish passive immunity. Furthermore, almost all of the surviving mice also withstood rechallenge with the same dose of virus 13 or 21 days after initial infection. The observation of this difference in the effectiveness of helenine in preventing passive immunization with heterologous (swine) but not homologous (mouse) antiviral serum suggested the possibility that the blocking effect of helenine might be directed not against the antibody itself, but rather against foreign protein labeled as antibody. Persistence of Viral Antibody inSera of Mice Injected with Anti-Semliki Serum.
--It has been suggested earlier in this paper in connection with the findings recorded in Table I that the persistence of antibody in the circulation for somewhat over a week might account for the failure of helenine to interfere with passive protection when the challenge with virus was given soon after the administration of antiserum and helenine. The findings detailed in the preceding section and recorded in Table IV, indicating that helenlne failed completely to interfere with the establishment of passive viral immunity by anti-Semliki serum of mouse origin further raised the question of whether perhaps there might be a difference in the time of persistence in the circulation of anti-Semliki serum of swine or mouse origin. To settle the point, mice were injected intraperitoneally with either swine or mouse anti-Semliki serum of approximately similar neutralizing titers. 3, 6, and 15 days later, blood was collected by de-capitation under anesthesia from groups of 7 animals receiving each type of antiserum and the pooled sera from each group tested in mice for the presence of neutralizing antibody.
The results recorded in Table V are not particularly clear-cut. However, on the basis of prolongation of survival time of the mice receiving mixtures contalnlng some of the sera under test, compared with the survival time of the con- trol mice, there is evidence that the sera obtained from mice 3 and 6 days after they had received either swine or mouse anti-Semlild serum contained small amounts of protective antibody. The sera drawn from mice 15 days after they had received anti-Semliki serum contained little if any protective antibody. So far as can be tom from the findings, the mouse anti-Semliki serum persisted in the circulation of injected mice only slightly if at all longer than that from swine. Certainly any difference that exists is not sufficient to account for the differences observed in the effectiveness of helenine in suppressing the establishment of passive viral protection by the two types of antiserum.
The Effect of Helenine on the Passive Immunization of Mice to Semliki Forest Virus by Various Heterologous and Homologous Anti-Sendiki Sera
In order further to explore the possibility that the interference of helenine with the establishment of passive viral immunity by antiserum of swine origin was a function of the heterologous nature of the antiserum, tests were carried out with anti-Semliki sera prepared in two other heterologous hosts. Rabbits and guinea pigs were immunized to Semliki Forest virus, as described earlier, to furnish two other antisera that, like that prepared in swine, would be heterologous to the mouse in which they were to be tested. A comparison of the effectiveness of helenine in modifying the establishment of passive immunity by three heterologous antiviral sera together with its failure to influence the establishment of passive immunity by two samples of homologous (mouse) antiviral sera will be presented.
Six groups of 28 or more mice each were injected intraperitoneally with antiSemliki serum prepared respectively in swine (two samples), rabbits, guinea pigs, and mice (two groups). 4 hr preceding the injection of antiserum, one half of each of the groups of mice received helenine intraperitoneally. The virus neutralizing titers of the six antiserum samples, as determined by intraperitoneal injection into mice of mixtures of a fixed amount of virus with diminishing amounts of antiserum, indicated that not more than a 50-fold difference in neutralizing titer existed between any of the serum samples. Ranged in order from highest to lowest neutralizing potency, the six antiserum samples tested were guinea pig, rabbit, swine A, mouse pool A, swine B, and mouse pool B.
18 days after the administration of antiserum, all of the treated mice together with 27 control animals were inoculated subcutaneously with Semliki Forest virus. The results of this experiment are outlined in Table VI .
As shown in Table VI , all six of the antiserum samples given alone effectively protected mice against a regularly fatal dose of Semliki Forest virus administered 18 days later and their species of origin seemingly did not influence their effectiveness. The results obtained on challenging the mice that had received the same six samples of antisera 4 hr after helenine were, however, quite different for among these groups only the antisera of mouse origin gave full protection. The mice in groups that had received antisera of swine, rabbit or guinea pig origin, preceded by helenine, were largely not protected against the challenge virus, indicating that the helenine had in some way prevented the establishment of passive protection by these heterologous antiviral sera. That the virus neutralizing titers of these sera played no significant role in the results obtained is indicated by the fact that mouse pool B anti-Semliki serum had the lowest titer of any of the others in the experiment and the titer of the mouse pool A serum was below that of the guinea pig, rabbit, and swine A sera.
These findings made it apparent that the capacity of helenine to prevent the establishment of passive protection to Semliki Forest virus in mice by various species types of anti-Semliki serum was in some way associated with the origin of the antiserum from hosts heterologous to mice in which the tests were conducted. The most likely explanation for the results obtained would seem to be that helenine, in some as yet unexplained manner, enhances the mouse's capacity to recognize the heterologous nature of these foreign host proteins and ~VrIVI~L SUBSTANCE FROM PENICILLIUM FUNICULOSUM. VI prevent their establishment. The failure of helenine to interfere with the establishment of passive immunity conferred by viral antibody in homologous (mouse) serum serves further to indicate strongly its action is not on antibody per se but rather on the gamma globulin comprising the antibody. The action appears to affect foreign protein and is detectable in the tests conducted merely because the heterologous protein is labeled as viral antibody. Since infected mouse brain had been employed in immunizing the mice, swine, 
Mouse pool A anfi-Semliki serum 4 hr after helenine
Guinea pig No. of mice in group rabbits, and guinea pigs supplying the antiviral sera in these experiments, and since challenge of the passively protected mice had been with infected mouse brain, there seemed some remote possibility that anti-mouse antibodies conceivably induced in the sera of the heterologous hosts might, in some obscure manner, have influenced the outcome of these experiments. In order to rule out such a possibility, groups of mice were injected with representative heterologous and homologous antiviral sera, either alone or in conjunction with helenine. 18 days later these animals were inoculated with Semliki Forest virus in infected guinea pig instead of infected mouse brain. The results parallded in their entirety those recorded in Table VI, indicating that the mousiness of neither the antivlral serum nor the challenge virus had influenced the experimental outcome.
Attempted Exhaustion of the Capacity of Hdenine to Interfere with the Establiskraent of Passive Viral
Immunity.--In earlier work (2) it was shown that repeated injections of helenine at 2-or 3-day intervals weakened or abolished its antivirus effect against Semllki Forest virus. Subsequent work (3) has indicated that the antivirus effect of helenine results from its induction of interferon in hosts to which it is administered. The finding that the antivirus effect could be exhausted by multiple injections of helenine was taken as evidence that the induced antivirus material was either present in limited supply in host cells or was capable of only limited elaboration there.
In order to learn whether the capacity of helenine to interfere with the estab- lishment of passive immunity by heterologous viruS antiserum was directly related to its antiviruS activity, an experiment has been conducted to test the possibility. In this experiment, swine anti-Sem|ikl serum usonewas administered to one group of mice and to a second group, a single injection of helenine was administered 4 hr before the swine anti-Semlikl serum. In the case of a third group of mice, 6 injections of helenine were given at 2-or 3-day intervuss before the final dose of helenine was injected 4 hr before the administration of the swine anti-Semliki serum. As shown by the results recorded in Table VII, 13 out of the 14 mice that had received anti-Semliki serum alone survived a stiff challenge with virus 18 days later. However, only 2 out of 20 mice that received helenine 4 hr before the swine anti-Semlikl serum survived. Among the group of 21 animals that received 6 injections of helenine at 2-or 3-day intervals prior to the helenine injection 4 hr before swine anti-Semlikl serum, none survived the challenge with virus 18 days later. This result indicated that multiple preceding injections of belenine did not exhaust or abolish its effectiveness in preventing the establishment of passive virus immunity by heterologous antivirus serum.
Since multiple preceding injections had effectively diminished the antiviral effectiveness of helenine, presumably mediated through its induction of interferon, it appeared superficially either that the antipassive immunity effect must have a different basic mechanism than the antiviral effect or that, if the phenomena had the same basis, there were marked quantitative differences in the hosts' response in the two reactions.
A Comparison of Hdenine and Statolon in the Prevention of the Establishment of Passive Viral Immunity by Swine A nli-Semliki Serum--Since both helenine
(3) and statolon (4) share the property of inducing the production of interferon in hosts to which they are administered, it seemed that a comparison of the two for their ability to prevent the establishment of passive viral immunity would prove instructive in determining whether this phenomenon might be one mediated by interferon. If statolon failed to interfere with the establishment of passive immunity by antiviral serum, it would suggest strongly that interferon played no role, while if it, like helenine, did suppress passive immunization, the finding would suggest the possible involvement of interferon. Three groups of mice were injected intraperitoneaUy with anti-Semtiki serum of swine origin. 2 hr later two of the groups of animals that had received antiserum were injected intraperitoneally, one with helenine and the other with statolon. These, together with an untreated control group, were held under observation for 20 days. The animals that had received antiserum and statolon (2.5 mg per mouse) looked rough for several days and 3 of the 14 in the group died. 20 days after the administration of antiserum, all groups of animals were challenged subcutaneously with a stiff dose (approximately 1000 MLD) of Semliki Forest virus. The 11 mice surviving in the statolon group had by then recovered and appeared completely normal.
TABLE VIII
Comparison of Effectiveness of Helenine and Slatolon in Preventing the Establishment of Passive Immunity to Semliki Forest Virus by Swine Anti-Semliki Serum
As shown by the findings recorded in Table viii , s out of the 7 mice that had been given antiviral serum survived a challenge infection that killed all of 15 control mice. In contrast, of the 14 mice that had received the antivirM serum followed by helenine, only one withstood the virus challenge, while of the 11 mice remaining in the group that had been given the antiviral serum followed by statolon, none survived challenge. These results indicated that statolon, like helenine, was capable of preventing the establishment of passive viral immunity by antiviral serum of swine origin. These two antiviral materials of reputed differing chemical composition (5, 6) , but both known to be capable of inducing the production of interferon, thus shared yet another activity, that of interfering with the establishment in the mouse of passive viral immunity by antiviral sera heterologous to that host. The possibility that interferon mediates both the antiviral and the antiforelgn immune protein activities of helenine and statolon appears as one requiring more definitive study and one that will be considered more in detail in a subsequent publication.
DISCUSSION
All of the evidence obtained in this study indicates that the action of helenine in preventing the establishment of passive viral immunity by antiviral serums of various foreign host sources results not from its effect upon antiviral antibody itself but rather from its effect upon the foreign host gamma globulin comprising the antibody. That the action is not directly on viral antibody is indicated by the complete inability of helenine to interfere with the establishment of passive viral immunity in mice by antibody of mouse origin. Viral antibody prepared in swine, rabbits, or guinea pigs, on the other hand, is completely prevented from establishing passive immunity in mice if helenine is administered to the mice during a period extending from 4 days before to 2 days after the antiserum. During this period of approximately 6 days, helenlne in some as yet unexplained manner prevents mice from acquiring passive viral immunity following the administration of the heterologous antiviral sera. So far as can be told, the heterologous and the homologous antiviral sera are of comparable efficacy in passively protecting mice against infection with Semllki Forest virus if treatment with helenine is withheld. The most probable interpretation of the findings under discussion, therefore, would seem to be that helenine exerts its effect on the establishment of passive viral immunity by virtue of some action that it has on the foreign gamma globulin comprising the viral antibody. The prevention of the establishment of passive viral immunity in mice by heterologous viral antibody is an effect made experimentally apparent only by virtue of the fact that the heterologous gamma globulin, the material against which the helenine effect is expressed, happens to be labeled as viral antibody.
The failure of helenine to exert any effect on the establishment of passive viral ~mmunity by homologous antiserum coupled with its marked effectiveness in preventing passive viral immunity by heterologous antiserum in the experiments under discussion permit of yet another rather self-evident conclusion. This is that helenine does not exert its effect directly but rather through inducing the host itself to elaborate the principle capable of selectively acting on the gamma globulin comprising the viral antibody. Were the action of helenine a direct one against immune viral gamma globulin, one would anticipate that it should be equally effective against either homologous or heterologous immune protein. Since it is not, but seemingly selects heterologous gamma globulin for its effect, the most apparent explanation would seem to be that the activity resides in some material, probably naturally present in small quantity in the host under normal conditions, that is induced in excess quantity when the host is treated with helenine. This induced material, whatever its nature may be, seemingly enhances the capacity of the host to recognize and dispose of foreign protein. As a result, the helenine-treated host handles foreign gamma globulin in such a maner as to prevent its establishment. Since the gamma globulin in the present instance is Semliki Forest virus antibody, animals treated with helenine do not establish passive immunity to that virus. This induced material, being of host origin, evidently does not recognize homologous gamma globulin and hence helenine does not prevent the establishment of passive immunity originating from the administration of homologous antibody.
As was pointed out in an earlier paper (3) dealing with the mechanism of the antiviral action of helenine, one of the mechanisms, and the most likely one, by which helenine effects its antiviral activity is through the induction of interferon in the helenine-treated host. In the experiments being presently discussed, helenine induces interferon just as it did in the earlier antiviral experiments. However whether this induced interferon accounts for the action that helenine exerts in disposing of immune gamma globulin, as it is known to do in preventing viral infection, cannot be decided from the data so far at hand.
In the work under discussion, several types of experiments have been carried out in an effort to learn whether the prevention of the establishment of passive immunity from heterologous antiviral serum by helenine could, like its antiviral effect (2, 3) , result from the induction of interferon in the host. Unfortunately the experimental work so far carried out and presented in this paper does not permit of a clear-cut decision as to whether interferon induced by helenine accounts for its capacity to prevent the establishment of passive immunity by heterologous antiviral serums although they do not categorically rule out the possibility.
The first experiment designed to test for a parallelism between the antiviral (AV) and the antipassive immunity (API) effects of helenine was the one recorded in Table III . It had been shown in an earlier publication (2) that helenine exerted its optimal AV effect during a period of 36 hr, beginning after about 12 hr and extending to 48 hr before virus infection. Since evidence has been presented to indicate that this AV effect resulted from interferon-induction in the treated host (3), it is apparent that, were the API effect of hdenine also mediated through induced interferon, its period of optimal effectiveness might be expected to parallel timewise the period of optimal AV activity. The results gotten in the experiments under present discussion obviously were not parallel with the earlier AV findings in that hdenine exerted an optimal API effect for at least 4 days before to 2 days after antiserum administration. While this 6 day period of optimal API effectiveness included the 36 hr period during which, as shown by earlier work (2), helenine exercised its optimal AV action, it extended well beyond the AV period in both directions. From the experiments under discussion, the suggestion is apparent that, although helenine probably exerts its AV effect through interferon induction in the treated host, evidence that induced interferon is responsible for the API effect of helenine seems less likely. However, the findings do not decisively rule out the possibility and the lack of parallelism between the time of optimal effectiveness of hdenine in consumating the two effects may reflect merely a quantitative difference in the sensitivity of the host to induced interferon in expressing the AV and the API effects.
The second experiment designed to test for a parallelism between the AV and API effects of helenine was the one recorded in Table VII . It had been previousiy shown, as reported in an earlier paper (2) that the AV effect of helenine could be diminished or exhausted if multiple injections at 2-or 3-day intervals preceded the final AV injection of hdenine. Based on the premise that the AV effect of helenine resulted from the induction of interferon in the injected host, the finding was interpreted as indicating that the capacity of a host to elaborate interferon under prolonged hdenine stimulation was finite and exhanstible, and that the eventual failure of helenine to exert its expected AV effect furnished tangible evidence for this eventual abolition of interferon elaboration. In the experiments carried out in the present work, multiple injections of helenine were given to mice preceding the final injection to elicit the API effect. It had been anticipated, if the mechanism by which helenine brought about the API effect and that by which it caused the AV effect were gmilar, that the API effect should be abolished just as had been the AV effect. However, such did not prove to be the case and the findings indicated that even six injections of helenine at 2-or 3-day intervals prior to a final injection 4 hr before antiserum administration did not abolish or even apparently diminish the API effect of helenine. Since multiple preceding injections of helenine had effectively exhausted its AV effect, presumably mediated through the induction of interferon, it appeared superficially at least either that the API effect of hdenine had a different basic mechanism than the AV effect or that, if the phenomena had the same basis, there were marked quantitative differences in the hosts' response in the two reactions. A point of difference in the two reactions which probably should be taken into account concerns the fact that the optimal period of effectiveness of helenine in the AV effect extends over a period of only 36 hr whereas the API effect embraces a period of 6 days during which helenine is optimally effective in bringing it about. This difference in the period of optimal activity of helenine in expressing its AV and API effects, coupled with a possible difference in the sensitivity of the host's response to the substance, induced by helenine, might account for a detectable lack of parallelism in the experiments under discussion.
The third experiment designed to test for a parallelism between the AV and API effects of helenine was the one recorded in Table VIII . In this, helenine and statolon, both substances known to induce the elaboration of interferon in hosts to which administered (3, 4) , and both capable of exerting pronounced AV effects, were found also both to exercise a maximal API effect when tested under similar conditions. Thus the parallelism as regards interferon induction and the manifestation of both an AV and an API effect was perfect so far as a comparative study of helenine and statolon could determine. The result of this third experiment suggested that there should be further serious study of the possibility that the API effect like the AV effect of helenine was mediated by induced interferon. Experiments of a more definitive character dealing with the possible role of interferon in the API effect of helenine are in progress and will be reported later. SUMMAR~ 1. Helenine prevents the establishment in mice of passive viral immunity by anti-Semlikl serum of swine, rabbit, or guinea pig origin.
2. A period of 12 days must elapse, between the antiviral serum administration and challenge with virus, for prevention of the establishment of passive immunity to become apparent. This period is believed to correspond to that in which injected antibody persists in circulation in the injected host.
3. Helenine is effective in preventing the establishment of passive viral immunity by heterologous antiviral sera when it is administered any time during a period of 6 days, extending from 4 days before to 2 days after injection of the antiviral serum.
4. Helenine does not prevent the establishment of passive viral immunity by antiviral sera of mouse origin (homologous).
5. Evidence is presented to indicate that the phenomenon of the prevention of the establishment of passive viral immunity by heterologous antiviral sera is not effected directly, but rather is mediated through some substance that helenine induces the injected host to elaborate.
6. The capacity to prevent the establishment of passive viral immunity could not be exhausted by repeated preceding injections of helenine at 2-or 3-day intervals.
7. Evidence is presented to indicate that the helenine-induced material does not act upon antiviral antibody per se but rather on heterologous foreign protein that happens to be labeled as Semliki Forest virus antibody. This helenineinduced material, whatever its nature, appears to enhance the capacity of the injected host to recognize and dispose of foreign protein.
8. Statolon, a material that like helenine is a known inducer of interferon, is, like helenine, also capable of preventing the establishment of passive viral immunity by heterologous antiviral sera.
9. Experiments designed to determine whether the induced material responsible for the antipassive immunity effect of helenine is interferon have yielded inconclusive answers thus far.
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